GLOBAL COALITION FOR ADAPTIVE RESEARCH INC
Programs
Program 1 [2020]
GBM AGILE (GLIOBLASTOMA ADAPTIVE GLOBAL INNOVATIVE LEARNING ENVIRONMENT) IS UNIQUELY DESIGNED AS A LONG-STANDING PLATFORM WITH THE ABILITY TO TEST MULTIPLE THERAPIES AT THE SAME TIME AGAINST A COMMON CONTROL (OR STANDARD OF CARE). THE PURPOSE IS TO EVALUATE MULTIPLE INVESTIGATIONAL TREATMENTS FOR EITHER NEWLY DIAGNOSED OR RECURRENT GLIOBLASTOMA TO DETERMINE IF ANY OF THESE STUDY TREATMENT(S) IMPROVE OVERALL SURVIVAL AS COMPARED TO STANDARD TREATMENTS.GeographiesNot indicatedDatesJan 1, 2020 – Dec 31, 2020Source990No causes providedNo populations provided–$8.4MProgram 2 [2020]
REMAP-COVID THE OBJECTIVE OF REMAP-COVID IS TO REDUCE MORTALITY AND MORBIDITY IN PATIENTS HOSPITALIZED WITH COVID-19 INFECTION BY QUICKLY GENERATING NEW EVIDENCE ON AVAILABLE AND NOVEL TREATMENTS. THROUGH PARTNERSHIPS WITH ACADEMIA, INDUSTRY AND MULTIPLE HEALTHCARE SYSTEMS, GCAR IS SPONSORING REMAP-COVID IN THE US WITH THE UNIVERSITY OF PITTSBURGH SERVING AS THE US REGIONAL COORDINATING CENTER FOR REMAP-CAP.GeographiesNot indicatedDatesJan 1, 2020 – Dec 31, 2020Source990No causes providedNo populations provided–$1.2MGBM Agile Initiative
GLIOBLASTOMA ADAPTIVE GLOBAL INNOVATIVE LEARNING ENVIRONMENT (GBM AGILE), GCAR'S INITIAL AND MOST ADVANCED INITIATIVE, IS A GLOBAL PHASE 2/3 ADAPTIVE PLATFORM TRIAL, DESIGNED TO EVALUATE MULTIPLE INVESTIGATIONAL TREATMENTS FOR GLIOBLASTOMA OVER TIME IN AN EFFORT TO IMPROVE PATIENT OUTCOMES. GBM AGILE HAS BEEN OPEN AND ENROLLING PATIENTS SINCE JULY 2019 WITH OVER 1,900 PATIENTS SCREENED TO DATE. IN 2023, SEVERAL PUBLICATIONS /PRESENTATIONS WERE CONDUCTED TO PRESENT DATA AND LATEST PROGRESS TO THE RESEARCH COMMUNITY, INCLUDING THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, EUROPEAN ASSOCIATION OF NEURO-ONCOLOGY, AND THE SOCIETY FOR NEURO-ONCOLOGY. ADDITIONALLY, GCAR PROVIDES ON-GOING SUPPORT TO THE GBM RESEARCH AND CLINICAL COMMUNITY THROUGH PHILANTHROPIC DONATIONS TO ADVOCACY GROUPS, AS WELL AS EDUCATION, OUTREACH AND CLINICAL COMMUNITY ENGAGEMENT. TO PROMOTE BRAIN CANCER AWARENESS IN 2023, GCAR PARTICIPATED IN ADVOCACY PARTNER FUND RAISING EVENTS, PANEL DISCUSSIONS, AND ACADEMIC CONFERENCES. NOTABLE HIGHLIGHTS INCLUDED RINGING THE NASDAQ CLOSING BELL ALONGSIDE PATIENTS, ADVOCACY PARTNERS, AND PHARMACEUTICAL PARTNERS TO PROMOTE BRAIN TUMOR AWARENESS MONTH AND PARTICIPATING IN THE WHITE HOUSE CANCER MOONSHOT FORUM ON BRAIN CANCER.GeographiesNot indicatedDatesJan 1, 2023 – Dec 31, 2023Source990No causes providedNo populations provided–$25.5M
Copyright 2026. All rights reserved to Chario Inc. (d.b.a. Impala)